Insider filing · ETON

Opaleye Management Inc. bought $312K of Eton Pharmaceuticals (ETON)

Executed Oct 4 2024, disclosed Oct 8 2024, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Oct 8 2024), the stock returned +16.3% (delay-adjusted); from the execution session (Oct 4 2024), +23.1%. Derived: entry at the session's open, exit at the close 20 sessions later.

OI Opaleye Management Inc. 10% owner profile →

Opaleye Management Inc. (10% owner) filed 36 Form 4 reports as a reporting entity in the trailing twelve months (22 purchases, 14 sales, 3 filed past the two-business-day deadline), most often in CDXS. Across 18 priced purchase filings, the average 21-session return was +19.2% from execution and +19.4% from disclosure (delay-adjusted; derived). The largest single filing was $7.8M of HROW (197,263 sh across 3 lots, as filed), executed Mar 3.

ETON Eton Pharmaceuticals, Inc. ETON · Healthcare · 14 filings in 24 months ticker →

Healthcare · Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→